Monthly formulary amendments – November 2025
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in November 2025.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Docusate for constipation
Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.
This document aims to review the evidence base for the use of docusate in the management of constipation, and discusses the over prescribing of laxatives in general.
Clascoterone for the treatment of acne vulgaris
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. The aim of this publication is to evaluate the efficacy, safety and potential place in therapy of Clascoterone cream a first-in-class androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
A Formulary Assessment Tool is also available on this topic. Formulary Assessment Tools are pre-populated templates with space for local adaptation, to reduce duplication and support decision-making
Anakinra for immuno-oncologic meningoencephalitis
RDTC D&T reviews are prepared in response to specific requests. They are intended for use by drug and therapeutics groups or equivalent committees, to support the review of applications to use a treatment in an individual or cohort. They are not intended to be used as standalone publications
A copy of this review is available on request from nuth.nyrdtc.rxsupp@nhs.net.
EBV cytotoxic T-cells for lymphoproliferative disease
RDTC D&T reviews are prepared in response to specific requests. They are intended for use by drug and therapeutics groups or equivalent committees, to support the review of applications to use a treatment in an individual or cohort. They are not intended to be used as standalone publications
A copy of this review is available on request from nuth.nyrdtc.rxsupp@nhs.net.
Daratumumab for steroid-sensitive nephrotic syndrome
RDTC D&T reviews are prepared in response to specific requests. They are intended for use by drug and therapeutics groups or equivalent committees, to support the review of applications to use a treatment in an individual or cohort. They are not intended to be used as standalone publications
A copy of this review is available on request from nuth.nyrdtc.rxsupp@nhs.net.
Benralizumab combination therapy for severe asthma
RDTC D&T reviews are prepared in response to specific requests. They are intended for use by drug and therapeutics groups or equivalent committees, to support the review of applications to use a treatment in an individual or cohort. They are not intended to be used as standalone publications
A copy of this review is available on request from nuth.nyrdtc.rxsupp@nhs.net.
Baricitinib for haploinsufficiency of A20
RDTC D&T reviews are prepared in response to specific requests. They are intended for use by drug and therapeutics groups or equivalent committees, to support the review of applications to use a treatment in an individual or cohort. They are not intended to be used as standalone publications
A copy of this review is available on request from nuth.nyrdtc.rxsupp@nhs.net.
Monthly Horizon Scanning Report – November 2025
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licences, significant new guidance, and decisions that have been made by recognised bodies.
This edition covers new and updated medicines and guidance published in October 2025.
This information is produced for use by NHS healthcare professionals.
Prescribing Update Newsletter – November/December 2024
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition focuses on the new NICE/BTS/SIGN asthma guidance and highlights some examples of the work we have carried out on your behalf in 2024. It also includes information on key medicines availability issues, recent RDTC publications, and the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources.
View the preview below on desktop, or click here to download a copy.